Markets:

Overview

News

Currencies

International

Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

23.95 -0.98 (-3.91%)

Streaming Delayed Price Updated: 11:26 AM EDT, Aug 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024 ↗

August 01, 2024

DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

August 01, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Stock Gets Technical Rating Upgrade ↗

July 16, 2024

Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗

July 08, 2024

Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery.

Via InvestorPlace

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

4 Analysts Assess Denali Therapeutics: What You Need To Know ↗

February 28, 2024

Via Benzinga

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

June 03, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗

May 08, 2024

Via Benzinga

DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 ↗

May 07, 2024

DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Denali Therapeutics: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

The Latest Analyst Ratings for Denali Therapeutics ↗

December 13, 2023

Via Benzinga

Where Denali Therapeutics Stands With Analysts ↗

November 08, 2023

Via Benzinga

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 07, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

May 01, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

To the Moon and Beyond: 7 Stocks With Cosmic Potential ↗

March 14, 2024

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.

Via InvestorPlace

Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know ↗

February 29, 2024

Via Benzinga

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗

February 27, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

Via Benzinga

Topics Stocks

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

February 27, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces $500 million Private Placement Equity Financing

February 27, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗

February 12, 2024

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.

Via Benzinga

3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗

February 08, 2024

These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.

Via InvestorPlace

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

February 07, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

February 01, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

January 08, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

3 Biotech Stocks at the Forefront of the Quest for Eternal Youth ↗

January 02, 2024

Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.

Via InvestorPlace

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

November 07, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗

November 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗

September 06, 2023

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.